You are here:

Vernalis has a lifeline

Created:
20 February 2008
Written by:
Richard Hemming

Embattled biotech Vernalis has achieved a rare few victory after US-based creditor Endo Pharmaceuticals wrote off a $56m (£28.8m) loan in return for a $7m upfront payment and future US royalties on Vernalis' migraine treatment, Frova.

Advertising

Piper Jaffray believes that the company's restructuring means its cash should now last until the end of 2009 and this, combined with the imminent exit of chief executive Simon Sturge, increases its takeover potential.


IC VIEW:

Sell

Maybe someone will buy Vernalis - but we doubt it will be on terms that are attractive to shareholders. Sell at 8.3p.


  • Back to top

Products and Services from Barclays Stockbrokers.

The UK’s No.1 Stockbroker

Stocks and Shares

Contracts for Difference

Financial Spread Trading

Gilts and Bonds

Funds Market

FX

Education Centre

Trading Simulator

Advertorial Feature

Spread your risks with spread trading

With so many big moves in the world's financial markets, there have seldom been more opportunities around for spread traders. Isn't it time you joined them?

by Dominic Piccarda